Compsit3 inc.
Complement-Based Imaging Diagnostics to Guide Personalized Medicine
Our Vision
Compsit3 is an early-stage molecular imaging company focused on the development and commercialization of molecular imaging probes for the non-invasive detection of tissue inflammation. Our lead technology is a probe for detecting tissue C3d, a robust marker of immune activation. C3d-imaging is better and safer than a tissue biopsy for the assessment of disease activity and therapeutic response to complement inhibitors and other immune modulators, and it will help clinicians to personalize each patient’s treatment. This will improve treatment, while also avoiding unnecessary drug side effects and additional biopsy procedures.
Why Compsit3
Next Generation of Diagnostics
During inflammation, the immune system marks affected tissues through the covalent attachment of millions of C3d molecules. CS-31 is an imaging probe that specifically targets and illuminates C3d deposited in tissues. Detection of C3d with CS-31 will provide clinicians with a comprehensive real-time overview of inflammation throughout the body. This information will reveal whether immunosuppressive treatment needs to be escalated because an inflammatory disease is still active, or whether treatment can be stopped because the disease is in remission.
Non-Dilutive Funding
Compsit3 received a $200,00 SPARK-Reach Colorado grant. We are currently seeking a $2.4M STTR Fast Track grant to support production of GMP (Good Manufacturing Practice) reagents and GLP (Good Laboratory Practice) pharmacology and toxicology to support the submission of an IND (Investigational New Drug) application to the FDA.
Partnership
Our goal is to develop CS-31 for clinical use. We are also open to partnering or collaborating with pharma companies and other industry partners. C3d-imaging can be used as a companion diagnostic for patient segmentation in clinical trials. This will be particularly useful for novel complement inhibitory drugs. C3d-imaging can be used to identify patients who have ongoing complement activation for enrollment, and it can also be used to non-invasively monitor the efficacy of the study drug at blocking complement activation specifically at the tissue site.
